HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Recent advances in leprosy and Buruli ulcer (Mycobacterium ulcerans infection).

AbstractPURPOSE OF REVIEW:
After tuberculosis, leprosy (Mycobacterium leprae) and Buruli ulcer (M. ulcerans infection) are the second and third most common mycobacterial infections in humankind, respectively. Recent advances in both diseases are summarized.
RECENT FINDINGS:
Leprosy remains a public health problem in some countries, and new case detections indicate active transmission. Newly identified M. lepromatosis, closely related to M. leprae, may cause disseminated leprosy in some regions. In genome-wide screening in China, leprosy susceptibility associates with polymorphisms in seven genes, many involved with innate immunity. World Health Organization multiple drug therapy administered for 1 or 2 years effectively arrests disseminated leprosy but disability remains a public health concern. Relapse is infrequent, often associated with higher pretreatment M. leprae burdens. M. ulcerans, a re-emerging environmental organism, arose from M. marinum and acquired a virulence plasmid coding for mycolactone, a necrotizing, immunosuppressive toxin. Geographically, there are multiple strains of M. ulcerans, with variable pathogenicity and immunogenicity. Molecular epidemiology is describing M. ulcerans evolution and genotypic variants. First-line therapy for Buruli ulcer is rifampin + streptomycin, sometimes with surgery, but improved regimens are needed.
SUMMARY:
Leprosy and Buruli ulcer are important infections with significant public health implications. Modern research is providing new insights into molecular epidemiology and pathogenesis, boding well for improved control strategies.
AuthorsDouglas S Walsh, Françoise Portaels, Wayne M Meyers
JournalCurrent opinion in infectious diseases (Curr Opin Infect Dis) Vol. 23 Issue 5 Pg. 445-55 (Oct 2010) ISSN: 1473-6527 [Electronic] United States
PMID20581668 (Publication Type: Journal Article, Review)
Chemical References
  • Anti-Bacterial Agents
Topics
  • Anti-Bacterial Agents (therapeutic use)
  • Buruli Ulcer (drug therapy, epidemiology)
  • Genetic Predisposition to Disease
  • Humans
  • Leprosy (drug therapy, epidemiology, genetics)
  • Molecular Epidemiology
  • Mycobacterium leprae (isolation & purification)
  • Mycobacterium ulcerans (classification, genetics, isolation & purification, pathogenicity)
  • Virulence

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: